Entact Bio
Michael Gutch currently serves as Chief Operating Officer at Entact Bio, a role assumed in May 2024, where the focus is on developing innovative precision medicines utilizing the Encompass™ platform. Previously, Michael was the Chief Financial Officer at Noema Pharma from February 2022 to March 2024 and held significant positions at Albireo as a Board Member and at Entasis Therapeutics as Chief Financial Officer/Chief Business Officer. Additionally, Michael contributed to AstraZeneca's corporate development as Executive Director and led venture capital efforts at MedImmune Ventures and H.I.G. BioVentures. Michael earned an MBA in Finance from Indiana University - Kelley School of Business and holds a Ph.D. in Molecular Pathology from Stony Brook University.
This person is not in any teams
This person is not in any offices
Entact Bio
1 followers
Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.